Catalyst Pharmaceuticals (NASDAQ:CPRX) Coverage Initiated by Analysts at Stephens

Stephens started coverage on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a report published on Monday morning, Marketbeat.com reports. The firm issued an overweight rating and a $35.00 price objective on the biopharmaceutical company’s stock.

CPRX has been the subject of a number of other reports. Citigroup increased their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. Finally, Truist Financial increased their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, November 11th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $31.14.

Catalyst Pharmaceuticals Stock Down 1.1 %

Shares of NASDAQ:CPRX opened at $21.15 on Monday. Catalyst Pharmaceuticals has a fifty-two week low of $13.00 and a fifty-two week high of $24.27. The company has a market cap of $2.52 billion, a PE ratio of 17.92, a P/E/G ratio of 3.17 and a beta of 0.75. The company’s 50-day moving average price is $21.09 and its 200 day moving average price is $18.47.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Arizona State Retirement System raised its stake in Catalyst Pharmaceuticals by 2.2% during the 2nd quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company’s stock valued at $461,000 after purchasing an additional 654 shares during the period. GAMMA Investing LLC raised its position in Catalyst Pharmaceuticals by 62.1% during the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 681 shares during the period. Ameritas Investment Partners Inc. lifted its stake in Catalyst Pharmaceuticals by 6.9% in the 1st quarter. Ameritas Investment Partners Inc. now owns 11,116 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 720 shares in the last quarter. XTX Topco Ltd boosted its position in Catalyst Pharmaceuticals by 7.5% during the 2nd quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company’s stock worth $172,000 after acquiring an additional 773 shares during the period. Finally, Strategic Advocates LLC grew its stake in Catalyst Pharmaceuticals by 6.5% during the 2nd quarter. Strategic Advocates LLC now owns 14,142 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 864 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.